From Wikipedia, the free encyclopediaJump to navigation Jump to search
|Chemical and physical data|
|Molar mass||146.8 kg/mol g·mol−1|
|NY (what is this?)|
Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
- LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897.
- Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
|Bone ("-os-", "-s(o)-")|
|Angiogenesis inhibitor ("-anibi-")|
|Growth factor ("-gr(o)-")|
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
Retrieved from "https://en.wikipedia.org/w/index.php?title=Icrucumab&oldid=886997162"